vs
NEOGEN CORP（NEOG）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是RESOURCES CONNECTION, INC.的1.9倍（$224.7M vs $117.7M），NEOGEN CORP净利率更高（-7.1% vs -10.8%，领先3.7%），NEOGEN CORP同比增速更快（-2.8% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $7.8M），过去两年NEOGEN CORP的营收复合增速更高（-0.9% vs -11.8%）
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
NEOG vs RGP — 直观对比
损益表 — Q2 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $224.7M | $117.7M |
| 净利润 | $-15.9M | $-12.7M |
| 毛利率 | 47.5% | 37.1% |
| 营业利润率 | -2.4% | -10.3% |
| 净利率 | -7.1% | -10.8% |
| 营收同比 | -2.8% | -19.2% |
| 净利润同比 | 96.5% | 81.6% |
| 每股收益（稀释后） | $-0.07 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $224.7M | $117.7M | ||
| Q3 25 | $209.2M | $120.2M | ||
| Q2 25 | $225.4M | $139.3M | ||
| Q1 25 | $221.0M | $129.4M | ||
| Q4 24 | $231.3M | $145.6M | ||
| Q3 24 | $217.0M | $136.9M | ||
| Q2 24 | $236.8M | $148.2M | ||
| Q1 24 | $228.8M | $151.3M |
| Q4 25 | $-15.9M | $-12.7M | ||
| Q3 25 | $36.3M | $-2.4M | ||
| Q2 25 | $-612.3M | $-73.3M | ||
| Q1 25 | $-10.9M | $-44.1M | ||
| Q4 24 | $-456.3M | $-68.7M | ||
| Q3 24 | $-12.6M | $-5.7M | ||
| Q2 24 | $-5.4M | $10.5M | ||
| Q1 24 | $-2.0M | $2.5M |
| Q4 25 | 47.5% | 37.1% | ||
| Q3 25 | 45.4% | 39.5% | ||
| Q2 25 | 41.2% | 40.2% | ||
| Q1 25 | 49.9% | 35.1% | ||
| Q4 24 | 49.0% | 38.5% | ||
| Q3 24 | 48.4% | 36.5% | ||
| Q2 24 | 47.9% | 40.2% | ||
| Q1 24 | 51.1% | 37.0% |
| Q4 25 | -2.4% | -10.3% | ||
| Q3 25 | -7.7% | -1.7% | ||
| Q2 25 | -271.1% | -47.0% | ||
| Q1 25 | 2.4% | -38.4% | ||
| Q4 24 | -197.8% | -52.7% | ||
| Q3 24 | 1.0% | -3.5% | ||
| Q2 24 | 5.5% | 7.6% | ||
| Q1 24 | 5.3% | 2.8% |
| Q4 25 | -7.1% | -10.8% | ||
| Q3 25 | 17.4% | -2.0% | ||
| Q2 25 | -271.6% | -52.6% | ||
| Q1 25 | -4.9% | -34.0% | ||
| Q4 24 | -197.3% | -47.2% | ||
| Q3 24 | -5.8% | -4.2% | ||
| Q2 24 | -2.3% | 7.1% | ||
| Q1 24 | -0.9% | 1.7% |
| Q4 25 | $-0.07 | $-0.38 | ||
| Q3 25 | $0.17 | $-0.07 | ||
| Q2 25 | $-2.82 | $-2.21 | ||
| Q1 25 | $-0.05 | $-1.34 | ||
| Q4 24 | $-2.10 | $-2.08 | ||
| Q3 24 | $-0.06 | $-0.17 | ||
| Q2 24 | $-0.02 | $0.31 | ||
| Q1 24 | $-0.01 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.3M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $194.6M |
| 总资产 | $3.4B | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $145.3M | $89.8M | ||
| Q3 25 | $138.9M | $77.5M | ||
| Q2 25 | $129.0M | $86.1M | ||
| Q1 25 | $127.7M | $72.5M | ||
| Q4 24 | $140.2M | $78.2M | ||
| Q3 24 | $120.5M | $89.6M | ||
| Q2 24 | $170.9M | $108.9M | ||
| Q1 24 | $168.4M | $113.8M |
| Q4 25 | $2.1B | $194.6M | ||
| Q3 25 | $2.1B | $206.4M | ||
| Q2 25 | $2.1B | $207.1M | ||
| Q1 25 | $2.7B | $277.8M | ||
| Q4 24 | $2.7B | $325.7M | ||
| Q3 24 | $3.1B | $407.2M | ||
| Q2 24 | $3.1B | $418.8M | ||
| Q1 24 | $3.1B | $414.9M |
| Q4 25 | $3.4B | $289.3M | ||
| Q3 25 | $3.4B | $287.2M | ||
| Q2 25 | $3.4B | $304.7M | ||
| Q1 25 | $4.0B | $375.6M | ||
| Q4 24 | $4.1B | $424.9M | ||
| Q3 24 | $4.5B | $512.9M | ||
| Q2 24 | $4.5B | $510.9M | ||
| Q1 24 | $4.6B | $523.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $7.8M | $15.6M |
| 自由现金流率自由现金流/营收 | 3.5% | 13.2% |
| 资本支出强度资本支出/营收 | 5.2% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $19.4M | $15.9M | ||
| Q3 25 | $10.9M | $-7.8M | ||
| Q2 25 | $16.4M | $16.8M | ||
| Q1 25 | $19.5M | $659.0K | ||
| Q4 24 | $40.3M | $1.8M | ||
| Q3 24 | $-17.9M | $-309.0K | ||
| Q2 24 | $26.7M | $3.2M | ||
| Q1 24 | $-30.2M | $20.5M |
| Q4 25 | $7.8M | $15.6M | ||
| Q3 25 | $-13.1M | $-8.0M | ||
| Q2 25 | $349.0K | $16.5M | ||
| Q1 25 | $-13.4M | $238.0K | ||
| Q4 24 | $23.1M | $61.0K | ||
| Q3 24 | $-56.3M | $-575.0K | ||
| Q2 24 | $2.5M | $3.0M | ||
| Q1 24 | $-62.3M | $20.4M |
| Q4 25 | 3.5% | 13.2% | ||
| Q3 25 | -6.3% | -6.6% | ||
| Q2 25 | 0.2% | 11.8% | ||
| Q1 25 | -6.1% | 0.2% | ||
| Q4 24 | 10.0% | 0.0% | ||
| Q3 24 | -26.0% | -0.4% | ||
| Q2 24 | 1.1% | 2.1% | ||
| Q1 24 | -27.2% | 13.5% |
| Q4 25 | 5.2% | 0.3% | ||
| Q3 25 | 11.5% | 0.1% | ||
| Q2 25 | 7.1% | 0.2% | ||
| Q1 25 | 14.9% | 0.3% | ||
| Q4 24 | 7.4% | 1.2% | ||
| Q3 24 | 17.7% | 0.2% | ||
| Q2 24 | 10.2% | 0.1% | ||
| Q1 24 | 14.0% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
